[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-329985-en":59,"doc-seo-329985-105":80},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":36},329985,1099513958607,"Jiven","https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Multimodal epigenetic sequencing analysis (MESA) of cell-free DNA for non-invasive colorectal cancer detection","Background Detecting human cancers through cell-free DNA (cfDNA) in blood offers sensitive, non-invasive testing, yet capturing multiple epigenetic signals is hindered by technical complexity and cost. Methods MESA was developed as a flexible, sensitive workflow using a single, non-disruptive bisulfite-free methylation sequencing assay to integrate diverse epigenetic features. Results Analysis of 690 cfDNA samples from three colorectal cancer cohorts shows improved detection beyond promoter DNA methylation. Conclusions MESA advances non-invasive cancer detection via comprehensive, complementary cfDNA epigenetic profiles.","Li etal. Genome Medicine (2024) 16:9 [https://doi.org/10.1186/s13073-023-01280-6](https://doi.org/10.1186/s13073-023-01280-6)  \nGenome Medicine  \n RESEARCH Open Access  \nMultimodal epigenetic sequencing analysis (MESA) of cell-free DNA for non-invasive colorectal cancer detection  \nYumei Li1,2†, Jianfeng Xu3†, Chaorong Chen1†, Zhenhai Lu4†, Desen Wan4, Diange Li5, Jason S. Li 1, Allison J. Sorg3, Curt C. Roberts3, Shivani Mahajan3, Maxime A. Gallant3, Itai Pinkoviezky3, Ya Cui1, David J. Taggart3* and Wei Li 1*  \nAbstract  \nBackground Detecting human cancers through cell-free DNA (cfDNA) in blood is a sensitive and non-invasive option. However, capturing multiple forms of epigenetic information remains a technical and financial challenge. Methods To address this, we developed multimodal epigenetic sequencing analysis (MESA), a flexible and sensitive approach to capturing and integrating a diverse range of epigenetic features in cfDNA using a single experimental assay, i. e., non-disruptive bisulfite-free methylation sequencing, such as Enzymatic Methyl-seq. MESA enables simultaneous inference of four epigenetic modalities: cfDNA methylation, nucleosome occupancy, nucleosome fuzziness, and windowed protection score for regions surrounding gene promoters and polyadenylation sites.  \nResults When applied to 690 cfDNA samples from 3 colorectal cancer clinical cohorts, MESA’s novel modalities, which include nucleosome fuzziness, and genomic features, including polyadenylation sites, improve cancer detection beyond the traditional epigenetic markers of promoter DNA methylation.  \nConclusions Together, MESA stands as a major advancement in the field by utilizing comprehensive and complementary epigenetic profiles of cfDNA for effective non-invasive cancer detection.  \nKeywords Liquid biopsy, Cancer detection, DNA methylation, Nucleosome, Polyadenylation  \n†Yumei Li, Jianfeng Xu, Chaorong Chen and Zhenhai Lu contributed equally to this work.  \n*Correspondence:  \nDavid J. Taggart [davidt@heliogenomics.com](davidt@heliogenomics.com)[ ](davidt@heliogenomics.com)Wei Li  \n[wei.li@uci.edu](wei.li@uci.edu)  \n1 Division of Computational Biomedicine, Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA 92697, USA  \n2 School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, P. R. China  \n3 Helio Genomics, Inc, Irvine, CA 92618, USA  \n4 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China  \n5 Guangzhou Youze Biological Pharmaceutical Technology Company Ltd, Guangzhou 510005, P. R. China  \nBackground  \nCancer has long been a leading cause of death worldwide. While research on cancer treatment continues to make progress in reducing cancer mortality, early detection provides the best opportunity to improve patient survival and lower treatment cost [1]. Recently, the analysis of circulating cfDNA — degraded DNA fragments in blood plasma originating primarily from the apoptosis of normal and diseased cells — has shown great potential for early cancer detection [2–4]. Using these liquid biopsies (non-invasive blood cfDNA-based detection methods) in routine screening is central to increasing surveillance adherence, identifying cancers in early curable stages, and ultimately reducing worldwide cancer mortality.  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material ","cbCaisyM0SvlaNDA","https://ap.wps.com/l/cbCaisyM0SvlaNDA","pdf",2938612,16,"English","en",105,"# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What problem does MESA address in cfDNA cancer testing?\",\"answer\":\"MESA targets the challenge of capturing multiple epigenetic information types from blood-derived cfDNA, which is often technically complex and costly.\"},{\"question\":\"How does MESA generate epigenetic information?\",\"answer\":\"MESA uses a single, non-disruptive bisulfite-free methylation sequencing assay to capture and integrate diverse epigenetic features in cfDNA.\"},{\"question\":\"What improvements did MESA show for colorectal cancer detection?\",\"answer\":\"Applied to 690 cfDNA samples from three clinical cohorts, MESA improved cancer detection beyond traditional promoter DNA methylation markers by leveraging additional modalities such as nucleosome fuzziness and genomic features including polyadenylation sites.\"}]","Multimodal epigenetic sequencing analysis (MESA) of cell-free DNA for non-invasive colorectal cancer detection | PDF",1789986445,{"code":4,"msg":81,"data":82},"ok",{"site_id":75,"language":74,"slug":83,"title":65,"keywords":84,"description":66,"schema_data":85,"social_meta":139,"head_meta":141,"extra_data":143,"updated_unix":144},"multimodal-epigenetic-sequencing-analysis-mesa-of-cell-free-dna-for-non-invasive-colorectal-cancer-detection","",{"@graph":86,"@context":138},[87,101,121],{"@type":88,"itemListElement":89},"BreadcrumbList",[90,94,96,99],{"item":91,"name":92,"@type":93,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":95,"name":9,"@type":93,"position":14},"https://docshare.wps.com/document/",{"item":97,"name":35,"@type":93,"position":98},"https://docshare.wps.com/document/healthcare/",3,{"item":100,"name":65,"@type":93,"position":19},"https://docshare.wps.com/document/multimodal-epigenetic-sequencing-analysis-mesa-of-cell-free-dna-for-non-invasive-colorectal-cancer-detection/329985/",{"url":100,"name":65,"@type":102,"image":103,"author":108,"headline":65,"publisher":110,"fileFormat":113,"inLanguage":74,"description":66,"dateModified":114,"datePublished":115,"encodingFormat":113,"isAccessibleForFree":116,"interactionStatistic":117},"DigitalDocument",{"url":104,"@type":105,"width":106,"height":107},"https://docshare.wps.com/thumbnails/multimodal-epigenetic-sequencing-analysis-mesa-of-cell-free-dna-for-non-invasive-colorectal-cancer-detection/329985.png","ImageObject",300,407,{"name":63,"@type":109},"Person",{"url":91,"name":111,"@type":112},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":118,"interactionType":119,"userInteractionCount":52},"InteractionCounter",{"@type":120},"ViewAction",{"@type":122,"mainEntity":123},"FAQPage",[124,130,134],{"name":125,"@type":126,"acceptedAnswer":127},"What problem does MESA address in cfDNA cancer testing?","Question",{"text":128,"@type":129},"MESA targets the challenge of capturing multiple epigenetic information types from blood-derived cfDNA, which is often technically complex and costly.","Answer",{"name":131,"@type":126,"acceptedAnswer":132},"How does MESA generate epigenetic information?",{"text":133,"@type":129},"MESA uses a single, non-disruptive bisulfite-free methylation sequencing assay to capture and integrate diverse epigenetic features in cfDNA.",{"name":135,"@type":126,"acceptedAnswer":136},"What improvements did MESA show for colorectal cancer detection?",{"text":137,"@type":129},"Applied to 690 cfDNA samples from three clinical cohorts, MESA improved cancer detection beyond traditional promoter DNA methylation markers by leveraging additional modalities such as nucleosome fuzziness and genomic features including polyadenylation sites.","https://schema.org",{"og:url":100,"og:type":140,"og:title":65,"og:site_name":111,"og:description":66},"article",{"robots":142,"canonical":100},"index,follow",{"doc_id":61,"site_id":75},1790129425]